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Aurora kinase A regulates Survivin stability through targeting
FBXL7 in gastric cancer drug resistance and prognosis
M Kamran1,5, Z-J Long2,5, D Xu3,5, S-S Lv1,5, B Liu1,5, C-L Wang1, J Xu1, EW-F Lam4 and Q Liu1,2
Aurora kinase A (AURKA) has been implicated in the regulation of cell cycle progression, mitosis and a key number of oncogenic
signaling pathways in various malignancies. However, little is known about its role in gastric cancer prognosis and genotoxic
resistance. Here we found that AURKA was highly overexpressed in gastric cancer and inversely correlated with disease prognosis.
Overexpression of AURKA exacerbated gastric cancer drug resistance through upregulating the expression of the anti-apoptotic
protein Survivin. Conversely, we demonstrated that AURKA depletion caused a decrease in Survivin protein levels by increasing its
ubiquitylation and degradation. Mass spectrometric analysis revealed that upon AURKA depletion, Survivin bound to the FBXL7 E3
ubiquitin ligase, which induced ubiquitin-proteasome degradation of Survivin. In addition, we showed that AURKA regulated FBXL7
both at the levels of transcription and translation. Moreover, proteomic analysis of nuclear AURKA-interacting proteins identiﬁed
Forkhead box protein P1 (FOXP1). We next showed that AURKA was required for FBXL7 transcription and that AURKA negatively
regulated FOXP1-mediated FBXL7 expression. The physiological relevance of the regulation of Survivin by AURKA through the
FOXP1–FBXL7 axis was further underscored by the signiﬁcant positive correlations between AURKA and Survivin expression in
gastric cancer patient samples. Moreover, the AURKA depletion or kinase inhibition-induced apoptotic cell death could be reversed
by Survivin ectopic overexpression, further supporting that AURKA regulated Survivin to enhance drug resistance. In agreement,
inhibition of AURKA synergistically enhanced the cytotoxic effect of DNA-damaging agents in cancer cells by suppressing Survivin
expression. Taken together, our data suggest that AURKA restricts Survivin ubiquitylation and degradation in gastric cancer to
promote drug resistance and hence the AURKA–Survivin axis can be targeted to promote the efﬁcacy of DNA-damaging agents in
gastric cancer.
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INTRODUCTION
Gastric cancer is one of the most common cancers with high
incidence of disease-related deaths and poor prognosis.1
Currently, surgical resection and chemotherapy are the most
effective treatments. However, patients with locally advanced
disease respond poorly to chemotherapeutic modalities, reﬂecting
an inherent refractive mechanism against drug-induced cell
death.2 Several previous reports have attempted to explore the
molecular markers that drive drug resistance. These proposed
markers and signatures, including PI3K/Akt, NFκB, inhibitors of
apoptosis (IAPs) and Bcl-2 family proteins, are highly expressed in
gastric cancer and associated with resistance to chemotherapy-
induced cell death.3,4
Aurora kinases were ﬁrst identiﬁed in Drosophila as key players
in chromosomal segregation.5 Subsequently, orthologues were
also discovered in humans and implicated in the control of distinct
and unrelated aspects of mitosis. Human Aurora kinase A (AURKA)
is essential for centrosome duplication, maturation and
separation.6 AURKA is a potent oncogene that has the capacity
to transform certain cell lines when overexpressed.7 Recent
evidence demonstrated that AURKA could regulate c-Myc expres-
sion through cooperating with hnRNP K.8 AURKA overexpression is
also a hallmark of many cancers and can enhance chromosomal
instability through centrosome ampliﬁcation. The human AURKA
gene maps to chromosome region 20q13.2, which is frequently
ampliﬁed in different malignancies, including gastric cancer.
A previous study showed that AURKA overexpression and
ampliﬁcation are involved in differentiated-type gastric carcino-
genesis and the development of aneuploidy, suggesting that it
might contribute to the initiation and progression of gastric
cancer.9 AURKA has also been implicated in taxane and
microtubule destabilizing drug resistance;10 however, its role in
gastric cancer, especially in resistance to DNA-damaging
therapeutic agents remains undeﬁned. Importantly, a previous
study using comparative genomic hybridization array found that
AURKA overexpression in high-risk primary gastric cancer tissues is
associated with dysregulated expression of DNA damage response
genes, which also include Survivin.11
Survivin is the smallest member of human IAPs and has two
critical but not yet fully elucidated roles in cell proliferation and
survival.12 First, Survivin is highly expressed in many human
malignancies and can restrict programmed cell death by inhibiting
the function of executioner caspases and procaspases. Secondly,
Survivin is also part of the chromosomal passenger complex
and responsible for recruiting chromosomal passenger complex
to mitotic chromosome, thus having a crucial role in genome
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stability. In addition to these widely studied functions, Survivin
also has an important but less well studied role in microtubule
stabilization.13 Survivin is an oncofetal protein with elevated
expression in stem and cancer cells, while expressed at low level in
normal adult differentiated cells.13–15 Survivin has been reported
to be overexpressed in both solid tumors and hematological
malignancies and its overexpression linked to drug resistance
in leukemia,16,17 breast cancer,18 neuroblastoma19 and ovarian
cancer.20 Survivin expression has both positive and negative
effects on clinical prognosis depending on its location. Nuclear
Survivin has been associated with a better prognosis, whereas
cytoplasmic Survivin is associated with in some cancer types poor
clinical outcome.21 In gastric cancer, the ﬁve-year survival rate of
patients with positive Survivin expression is signiﬁcantly lower
than Survivin-negative patients.22 Survivin protein undergoes
post-translational modiﬁcations, including acetylation, phosphor-
ylation and ubiquitylation,23 and these processes modulate
Survivin activity.
Although there is strong evidence that AURKA and Survivin are
simultaneously co-overexpressed in various malignancies, includ-
ing breast24 and chronic lymphocytic leukemia,25 relatively little is
known about their expression, regulation and function in gastric
cancer. In this study, we addressed this question and found that
AURKA and Survivin cooperated in gastric cancer development
and had a decisive role in resistance to DNA-damaging agents
and poor cancer prognosis. Moreover, we revealed that
AURKA stabilized Survivin protein by suppressing its protein
degradation through negatively regulating Forkhead box protein
P1 (FOXP1)-mediated FBXL7 expression.
RESULTS
AURKA expression correlates with poor prognosis in gastric cancer
We ﬁrst assessed the relationship between AURKA and gastric
cancer prognosis by immunohistochemical analysis. To this end,
we studied the expression of AURKA protein in a large cohort of
240 gastric cancer patients and found that 172 (71.7%) subjects
had high AURKA expression. To further validate our immuno-
histochemistry results, we performed western blot analysis of
paired samples from gastric tumors and their adjacent normal
tissues. Consistently, we found a higher AURKA expression in
gastric tumor tissues compared with their adjacent normal tissues
(Figure 1a). Clinicopathologic correlation analysis showed that
AURKA positivity was strongly correlated with a number of gastric
cancer clinical features. The AURKA staining was positively
correlated with tumor stage (P= 0.006), clinical stage (P= 0.002),
lymph node metastasis (P= 0.007) and distant metastasis
(Po0.0001). We did not ﬁnd a signiﬁcant correlation between
AURKA overexpression and gender, age, sex, tumor size, tumor
site and grading (Supplementary Table 1).
Moreover, gastric cancer patients with high AURKA showed
signiﬁcantly poorer disease free survival (DFS, P= 0.001) and
overall survival (OS, Po0.001) compared with low AURKA
expressing gastric cancer patients (Figure 1b). Univariate analysis
showed that survival time also decreased with tumor size (44 cm)
(DFS, Po0.001; OS, Po0.001), higher tumor stage (pT)
classiﬁcation (DFS, Po0.0001; OS, Po0.0001), lymph node
metastasis (DFS, Po0.0001; OS, Po0.0001) and advanced pTNM
stage (DFS, Po0.0001; OS, Po0.0001). There was no statistically
signiﬁcant correlation between DFS or OS and age, sex or tumor
grade (Supplementary Table 2). In multivariate, analysis both
lymph node metastasis (DFS, P= 0.002; OS, P= 0.007) and tumor
stage (DFS, Po0.0001; OS, Po0.0001) were signiﬁcant
independent prognostic factors for survival (Figure 1c). In addition,
multivariate analysis also indicated a signiﬁcant correlation
between AURKA expression and survival (DFS, P= 0.030; OS,
P= 0.016). Thus, we showed that AURKA level, as an independent
prognostic factor, was adversely associated with clinical
prognosis, suggesting that the poor chemotherapy response in
gastric cancer patients might be related to high AURKA expression
(Figure 1c).
Importantly, TUNEL assay showed that overexpression of
AURKA reversed cell apoptotic death caused by doxorubicin in
gastric cancer BGC823 cells (Figure 1d; Supplementary Figure 1).
Conversely, AURKA depletion by siRNA effectively increased
sensitivity to doxorubicin (Figure 1e), indicating that AURKA could
override DNA damage checkpoint to promote cell survival.
AURKA regulates Survivin expression in gastric cancer cells
To conﬁrm our hypothesis that AURKA modulates Survivin
expression in gastric cancer cells, we depleted endogenous
AURKA in gastric cancer cells and examined AURKA and Survivin
protein expression. The western blot analysis indicated Survivin
expression dramatically decreased in AURKA-depleted AGS and
BGC823 gastric cancer cells (Figure 2a), suggesting that AURKA
positively regulated Survivin expression. In agreement, AURKA
ectopic overexpression in both cells induced Survivin expression
levels (Figure 2b), indicating AURKA was an upstream regulator of
Survivin expression. It was noteworthy that silencing of AURKA
had little or no effects on mRNA levels in AGS and BGC823 cells
(Supplementary Figure 2), suggesting that AURKA regulated
Survivin at the post-transcriptional level. Further, AURKA small
molecule inhibitor VX-680 treatment also resulted in a marked
decreased in Survivin protein level in a kinase-dependent manner
(Figure 2c), indicating AURKA kinase activity was required for the
regulation of Survivin expression. To conﬁrm further that AURKA
mediated Survivin upregulation, we performed immunohisto-
chemistry of 62 pairs of gastric cancer specimens and found
that AURKA expression was positively correlated with Survivin
expression (r= 0.402; Po0.01; Figure 2d; Supplementary Table 3).
Considering that co-overexpression of AURKA and Survivin was
associated with poor prognosis of gastric carcinomas, we assessed
the effect of Survivin expression on drug sensitivity. To achieve
this, BGC283 cells were transfected with Survivin cDNA expressing
plasmid or siRNA sequences and treated with doxorubicin
followed by TUNNEL assay. As shown in Figures 2e and f, elevated
Survivin expression was correlated with decreased sensitivity to
doxorubicin while Survivin depletion exacerbated cell death
compared with control cells in response to the DNA-damaging
agent. Together, these data suggested that AURKA regulated
Survivin protein expression and upregulation of Survivin levels
was the critical mechanism by which AURKA caused gastric cancer
cell proliferation and drug resistance to doxorubicin.
VX-680 synergistically enhances the cytotoxic effect
of doxorubicin by suppression of survivin
We next sought to determine whether the small molecule AURKA
kinase inhibitor VX-680 might potentiate the genotoxic effects of
doxorubicin. To this end, BGC823 cells were treated with VX-680,
doxorubicin, or a combination of both, and the proliferation of the
cells analyzed by MTT assay. The combination of these two agents
strongly reduced cell proliferation. The inhibition rate of VX-680
and 0.5 μg/ml doxorubicin combination were 42.4% (q= 1.19) and
49.7% (q= 1.35), while VX-680 and 1 μg/ml doxorubicin combina-
tion were 59.7% (q= 1.39) and 67.4% (q= 1.51), respectively
(Figure 3a). Western blot showed that combination of these two
agents strongly reduced AURKA activity, with an increase in
cleaved PARP expression. Most importantly, Survivin expression
was induced by doxorubicin but was strongly reduced by the
combination treatment (Figure 3b). Moreover, VX-680 induced cell
death was signiﬁcantly (Po0.001) rescued by ectopic expression
of Survivin (Figure 3c), indicating that Survivin was one of the key
molecules targeted by AURKA signaling. Our results provided
evidence that AURKA expression correlated with cell response to
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Figure 1. AURKA expression is inversely correlated with gastric cancer prognosis and overrides DNA damage-induced cell death. (a) Western
blot analysis of AURKA expression in gastric cancer (T) and normal adjacent tissues (N). Whole-tissue extracts were prepared and western
blotting analysis performed with the indicated antibodies. GAPDH was used as internal loading control. (b) Kaplan–Meier survival analysis of
240 gastric cancer patients. Patients’ primary tissues were grouped by high and low AURKA staining values. High AURKA expression was
signiﬁcantly associated with the overall survival (OS) rate. (c) Multivariate cox regression analysis of disease-free survivals (DFS) and OS. 95% CI,
95% conﬁdence interval; HR, hazard rate. (d) BGC823 cells transfected with cDNA encoding wild-type AURKA were treated with or without
doxorubicin (1 μg/ml) for 48 h and subjected to western blot and TUNEL assay. Data represent means± s.e.m. of three independent
experiments with signiﬁcance determined by one-way ANOVA followed by Tukey’s multiple comparison test. (e) BGC823 cells transfected with
AURKA siRNA sequences were treated with or without doxorubicin (1 μg/ml) for 48 h and subjected to western blot and TUNEL assay. Data
represent means± s.e.m. of three independent experiments with signiﬁcance determined by one-way ANOVA followed by Tukey’s multiple
comparison test.
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chemotherapy and inhibition of AURKA might potentiate the
efﬁcacy of chemotherapeutic agent, such as doxorubicin for
gastric cancer therapy.
AURKA suppresses Survivin polyubiquitylation and proteasomal
degradation
Given that AURKA had little inﬂuence on Survivin mRNA levels,
we next explored the underlying mechanism for AURKA-mediated
Survivin expression. Depletion of AURKA led to increased Survivin
protein degradation following treatment with the translation
inhibitor cycloheximide (Figures 4a and b). Indeed, depletion
of AURKA reduced Survivin protein half-life, indicating that
AURKA stabilized Survivin and regulated Survivin levels via
post-translational mechanisms.
As AURKA has been shown to regulate protein ubiquitylation
and proteasomal degradation,10,26 we next asked whether
AURKA suppressed Survivin polyubiquitylation and proteasomal
degradation. We ﬁrst tested the effects of proteasome inhibitor
MG132 in conjunction with AURKA kinase inhibitor or siRNA
depletion on Survivin expression. Western blot analysis indicated
that AURKA kinase inhibition or siRNA depletion alone reduced
Survivin expression, whereas the addition of MG132 could rescue
its expression level (Figures 4c and d), suggesting that the Survivin
protein downregulation in response to AURKA kinase inhibition or
AURKA depletion was at least partially, due to ubiquitin-
proteasomal degradation. These ﬁndings were corroborated by
the in vivo Survivin ubiquitylation assay which showed that AURKA
knockdown decreased Survivin stability and this was associated
with an increase in its polyubiquitylation (Figure 4d).
AURKA modulates SCFFBXL7 to suppress Survivin degradation
Protein proteasomal degradation precedes orchestrated events
involving a series of enzymatic reactions comprising of E1
ubiquitin activating enzyme, E2 ubiquitin conjugating enzymes,
and E3 ubiquitin ligases. The E1 and E2 are common enzymes,
while E3 ubiquitin ligases are highly substrate speciﬁc.27
To delineate the E3 ligase responsible for Survivin degradation
controlled by AURKA in gastric cancer cells, we performed mass
spectrometry analysis of Survivin immunoprecipitates after
treatment with MG132 (data not shown) and identiﬁed a number
of putative Survivin-interacting E3 ubiquitin ligases. To conﬁrm
further our mass spectrometry-based data, we selected seven
Survivin-interacting proteins with potential E3 ligase activity,
and had the genes cloned and transiently expressed in BGC823
cells (Figure 5a). Amongst these E3 ligases, only FBXL7 when
overexpressed reduced Survivin expression at the protein level.
We then examined Survivin and FBXL7 interaction by transiently
co-expressing His-tagged Survivin and Flag-tagged FBXL7 in
HEK293T cells followed by coimmunoprecipitation (Figure 5b).
We found the Flag-tagged FBXL7 coprecipitated with His-tagged
FBXL7 and vice versa, but not with the control IgG, suggesting that
Survivin interacted with FBXL7 either directly or as part of a larger
complex. Next, we transiently transfected AGS and BGC823 cells
with increasing amounts of Flag-FBXL7 plasmid (Figure 5c) and
Figure 2. AURKA upregulates Survivin expression and sustains gastric cancer cell survival. (a) shRNA-mediated knockdown of AURKA
downregulates Survivin protein levels in AGS and BGC823 cells. Cells were infected with lentiviruses expressing shAURKA or control
scrambled RNA targeting GFP. A pool of resistant cells was selected by puromycin and cells were cultured in the presence of 1 μg/ml
doxycycline. Forty-eight hours after induction, cells were lysed and subjected to western blotting with the indicated antibodies. (b) AURKA
ectopic expression upregulates Survivin protein levels. Cells were transfected with control and AURKA expressing plasmids. After 24 hours,
cells lysates were immunoblotted with the indicated antibodies. (c) BGC823 cells were incubated with indicated doses of VX-680 for 24 h
before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The
relative expression shown (right panel) are means± s.e.m. of the ratios of Survivin to GAPDH. (d) Positive correlation between AURKA and
Survivin expression in gastric cancer patients. AURKA and Survivin expression was assessed by immunohistochemistry using gastric cancer
tissue samples from 62 patients. Representative staining images of one patient with high AURKA and Survivin and one with low expression
are shown. Images (magniﬁcation 200 × ). Positive correlation between AURKA and Survivin was observed. (e) BGC823 cells transfected with
cDNA encoding wild-type Survivin were treated with or without doxorubicin (1 μg/ml) for 48 h and subjected to Western blot and TUNEL
assay. Data represent means± s.e.m. of three independent experiments with signiﬁcance determined by one-way ANOVA followed by Tukey’s
multiple comparison test. (f) BGC823 cells transfected with Survivin siRNA sequences were treated with or without doxorubicin (1 μg/ml) for
48 h and subjected to Western blot and TUNEL assay. Data represent means± s.e.m. of three independent experiments with signiﬁcance
determined by one-way ANOVA followed by Tukey’s multiple comparison test.
Figure 3. VX-680 synergistically enhances the cytotoxic effect of
doxorubicin by suppression of Survivin. (a) BGC823 cells
were incubated with indicated doses of VX-680, doxorubicin,
or combination of both for 24 h before subjected to MTT assay.
Column, mean number of survived cells; Bar, s.d.; ***Po0.001
compared with control. (b) BGC823 cells were incubated with
VX-680, doxorubicin or combination of both for 24 h, and subjected
to western blot analysis with AURKA (T288), AURKA, Survivin, Bcl-2,
cleaved PARP and GAPDH antibodies. (c) Overexpression of Survivin
protects gastric cancer cells from VX-680-induced cell death.
BGC823 cells transiently overexpressing Survivin were treated with
VX-680 for 24 h before subjected to MTT assay. Column, mean
number of survived cells; Bar, s.d.; ***very signiﬁcant: Po0.001
compared with control.
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found Survivin protein levels decreased in a dose-dependent
manner in response to FBXL7 ectopic overexpression. To conﬁrm
the speciﬁcity of FBXL7 for Survivin, we puriﬁed all components
of ubiquitylation reaction using the prokaryotic protein
expression system and performed in vitro ubiquitylation analysis.
As indicated in Figure 5d, SCFFBXL7 promoted the generation of
polyubiquitylated Survivin species, thus conﬁrming that Survivin
was a speciﬁc substrate of the SCFFBXL7 E3 ligase complex.
Recent evidence demonstrated that AURKA could regulate
c-Myc expression through cooperating with hnRNP K,8 we
hypothesized that AURKA regulated FBXL7 expression in order
to control Survivin steady state. To test this hypothesis, we
depleted AURKA in both AGS and BGC823 cells and analyzed
FBXL7 expression. As shown in Figure 6a, AURKA depletion
signiﬁcantly increased FBXL7 protein levels. Consistent with the
Western blot results, FBXL7 mRNA levels also increased in AURKA
knockdown cells (Figure 6b), indicating AURKA regulates FBXL7
expression at the transcriptional level. It is noteworthy that
endogenous FBXL7 mRNA and protein levels were low in AURKA
wild-type gastric cancer cells; however, both FBXL7 mRNA and
protein levels reached detectable levels only after AURKA
depletion. To examine AURKA-mediated FBXL7 transcriptional
Figure 4. AURKA suppresses the degradation of Survivin in gastric cancer cells. (a and b) AGS and BGC823 cells stably expressing doxycycline-
inducible shAURKA or control cells were cultured in the presence of 1 μg/ml doxycycline. Forty-eight hours after induction, cells treated with
100 μg/ml cycloheximide for indicated times and cell lysates were immunoblotted with the indicated antibodies. Densitometry was used to
quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means± s.d. of the ratios of Survivin to GAPDH.
(c) BGC823 cells were treated with indicated doses of VX-680, with or without MG132 for 12 h before subjected to western blot analysis
with Survivin and GAPDH antibodies. (d) BGC823 cells stably expressing doxycycline-inducible shAURKA or control cells were transfected with
His-ubiquitin plasmid and cultured in the presence of 1 μg/ml doxycycline. Twenty-four hours after induction, cells were treated with 10 μM
MG132 for 6 h and subjected to immunoprecipitation with Survivin antibody. Survivin immunoprecipitates and inputs (1/10 of IP) were
subjected to Western blot analysis with the indicated antibodies. Western blots are representative of three independent experiments.
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activity, we cloned a 1.5 kb fragment of FBXL7 upstream of the
transcriptional start site into the pGL3 basic vector and tested for
its promoter activity. As shown in Figures 6c and d, both total
AURKA depletion and kinase activity inhibition signiﬁcantly
increased FBXL7 promoter activity, suggesting that AURKA
suppressed FBXL7 promoter activity in a kinase-dependent
manner.
FBXL7 suppression by AURKA is dependent on FOXP1
transcriptional activity
To further explore the possible mechanism by which AURKA
regulates FBXL7 expression, we examined putative transcription
factor binding sites in − 1.5 kb to +1 region of the FBXL7 promoter
region using the MatInspector module of the Genomatix
database28 (Supplementary Table 5). We also performed in vitro
GST pulldown assay to determine AURKA-interacting transcription
factors. For that purpose, we puriﬁed GST and GST-AURKA
proteins using prokaryotic expression system and incubated them
with nuclear and cytoplasmic fractions from AGS cells followed by
in vitro GST pulldown. The pulldown assay showed that AURKA
bound to about 35 proteins with transcription factor activity
Figure 5. SCFFBXL7 targets Survivin for polyubiquitylation and
proteasomal degradation. (a) Cells were transfected with control
plasmid pLVX or Flag-tagged F-box plasmids. After 24 h, cell lysates
were prepared and analyzed for Flag, AURKA, Survivin and GAPDH
immunoblotting. (b) Coimmunoprecipitation (co-IP) assay for
determination of FBXL7 and Survivin interaction. HEK293T cells
were transfected with Flag-tagged FBXL7 and His-tagged Survivin
and cultured for 24 h. Cells were lysed in co-IP buffer followed by
immunoprecipitation with rabbit Flag, His and control IgG anti-
bodies. Input (1/25 of IP) and immunoprecipitates were processed
for western blotting with the indicated antibodies. (c) Cells were
transfected with increasing amounts of FBXL7 plasmid. After 24 h,
cells were collected and processed for Flag, AURKA, Survivin and
GAPDH immunoblotting. (d) In vitro ubiquitylation of recombinant
Survivin with E1, E2, E3-FBXL7 or E3-FBXL13, SKP1, Cul1, RBX1 and
ubiquitin-Flag. Upon activation with ATP, samples were incubated at
30 °C for 30 min. The reaction was stopped by addition of SDS–PAGE
loading buffer and samples were boiled for 10 min. Polyubiquity-
lated Survivin was detected by immunoblotting with Flag antibody.
Figure 6. AURKA regulates FBXL7 expression through modulating its
promoter activity. (a) Western blot and (b) quantitative reverse
transcription–PCR (qRT–PCR) analysis were performed on AGS and
BGC823 cells stably expressing shAURKA or shNC. Cells were
cultured in the presence of 1 μg/ml doxycycline. Forty-eight hours
after induction, cells were harvested and processed for immuno-
blotting and qRT–PCR. The experiments were repeated three times
independently. Densitometry and qRT–PCR results were normalized
against GAPDH protein and mRNA levels, respectively. Data are
mean± s.d. of three independent experiment. (c and d) FBXL7
promoter activity in response to AURKA kinase inhibition and
shRNA-mediated AURKA depletion. Promoter activities in response
to dimethyl sulfoxide (DMSO) treatment or shNC were set as 100%
and other activities are relative to this. Data present means± s.e.m.
of three independent experiments and statistical analysis was
performed with one-way ANOVA, *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001.
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(Supplementary Table 6). Interestingly, SOX30 and FOXP1 were
two factors detected by the pulldown assay and the MatInspector
promoter-binding transcription factor analysis (Figure 7a).
To conﬁrm the in vitro GST-pulldown assay results, we transiently
transfected HEK293T cells with His-FOXP1 and AURKA plasmids
and performed coimmunoprecipitation studies and found that
Figure 7. AURKA negatively regulates FOXP1-mediated FBXL7 promoter activity. (a) AURKA-interacting transcription factor-like proteins were
identiﬁed using in vitro GST pulldown (red area). FBXL7 promoter-binding proteins were deduced from MatInspector analysis (green area).
FOXP1 was present in both data sets and selected for further studies. (b) HEK293T cells were transfected with His-tagged FOXP1 and AURKA
plasmids and whole-cell lysates co-immunoprecipitated with control IgG, His and AURKA antibodies. Input (1/25 of IP) and
immunoprecipitates were processed for immunoblotting with the indicated antibodies. (c) In silico protein–protein interaction between
AURKA and FOXP1. PDB ﬁles were obtained from PDB databank (http://www.rcsb.org/pdb) and analyzed for AURKA and FOXP1 interacting
residues using PRISM webserver (cosbi.ku.edu.tr/prism/). (d) Recruitment of FOXP1 and AURKA to FBXL7 promoter in gastric cancer cells.
AURKA and FOXP1 occupancy at the FBXL7 promoter was analyzed by chromatin immunoprecipitation (ChIP) using AURKA, FOXP1 and
control IgG antibodies. Input and ChIP DNA was processed for conventional PCR using three different primer pairs, spanning a 2 kb region of
FBXL7 promoter. (e) Validation of FBXL7 promoter as a direct target of FOXP1. HEK293T cells were transfected with empty pGL3 basic or
pGL3-FBXL7 promoter and pcDNA vector, AURKA and FOXP1 as activators. After 24 h, cells were harvested and processed for dual luciferase
activity. FBXL7 promoter activity in response to pcDNA vector was set 100% and compared with other samples. Each sample was transfected
in triplicates and three repeated experiments were performed in which similar results were obtained. (f) The luciferase activities of FBXL7
promoter 5′ deletion constructs in response to pcDNA vector or FOXP1. The − 1500 bp FBXL7 promoter activity was set as 100% and
compared with − 1000, − 500 and − 212 bp deletion constructs. FOXP1 strongly activated all 5′ deletion constructs afﬁrming that FBXL7
promoter has multiple FOXP1-binding sites. Each sample was transfected in triplicates and three independent experiments were performed in
which similar results were obtained. Data present mean± s.e.m. of three independent experiments and statistical analysis was performed with
one-way ANOVA, *P⩽ 0.05; **P⩽ 0.01; ***P⩽ 0.001.
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both AURKA and FOXP1 could pull down each other, but the
control antibody did not show any binding (Figure 7b), indicating
AURKA and FOXP1 indeed interacted with each other. Further-
more, we conﬁrmed protein–protein interaction between AURKA
and FOXP1 using PRISM database,29,30 which predicts the binding
site of two proteins using known template interfaces (Figure 7c).
PRISM analysis results further revealed that residues 507–519 of
FOXP1 located in forkhead domain might be involved in
interacting with residues 127–209 of AURKA (data not shown).
Moreover, mass spectrometry analysis of in vitro AURKA
phosphorylated FOXP1 (data not shown) identiﬁed S83, S104
and S440 FOXP1 (Supplementary Figure 3d) as putative AURKA
phosphorylated sites on FOXP1. Intriguingly, one of them (S440)
was located within the transactivation domain of FOXP1.31 It was
therefore conceivable that AURKA might target FOXP1 for
phosphorylation and transcriptional repression.
We then investigated the in vivo recruitment of FOXP1 to the
FBXL7 promoter by chromatin immunoprecipitation (ChIP).
As shown in Figure 7d, both FOXP1 and AURKA antibodies
could effectively immunoprecipitate the FBXL7 promoter DNA,
indicating both FOXP1 and AURKA, are recruited to the FBXL7
promoter directly or as part of a protein complex. Next, we
examined whether FOXP1 binding to FBXL7 promoter enhanced
FBXL7 gene expression. To this end, we performed luciferase
reporter assay in HEK293T cells using full-length wild-type FBXL7
promoter (Figure 7e). The reporter assay showed that AURKA
expression did not affect FBXL7 promoter activity, while FOXP1
increased considerably the FBXL7 promoter activity. Notably, the
expression of AURKA also signiﬁcantly repressed the induction of
FBXL7 promoter activity by FOXP1, suggesting AURKA modulated
FOXP1 activity to restrict FBXL7 expression, whereas in the
absence of AURKA, FOXP1 served as an activator of FBXL7
expression. To explore further the ability of FOXP1 to transactivate
the FBXL7 promoter, we generated FBXL7 promoter 5′-truncation
constructs to test their ability to be transactivated by FOXP1
(Figure 7f). The promoter/reporter assays showed that FOXP1
induced the promoter activity of all 5′ deletion constructs,
conﬁrming that FOXP1 could induce FBXL7 expression through
its promoter. Moreover, the results also strengthened the
MatInspector database ﬁndings that FOXP1 bound to multiple
sites on the FBXL7 promoter. In addition, we also determined
whether these transcriptional effects were mediated at the
translational level. We transfected AGS cells with the empty
pcDNA vector, AURKA, FOXP1, or FOXP1 and AURKA together,
and investigated the FBXL7 protein levels by immunoblotting.
As shown in Supplementary Figure 3a, ectopic expression of
AURKA signiﬁcantly downregulated FBXL7 protein levels,
while FOXP1 alone upregulated FBXL7 expression. However,
a combination of AURKA and FOXP1 again suppressed FBXL7
expression, indicating that AURKA negatively regulated FBXL7
expression through modulating FOXP1. Together, these results
suggest that AURKA targets FOXP1 to negatively regulate the
expression of FBXL7, which can in turn negatively regulate
Survivin protein levels in gastric cancer cells.
DISCUSSION
Mitotic kinases, including AURKA, are key signaling components of
genotoxic response pathways.32 Previous studies have documen-
ted aberrant expression of AURKA in various carcinomas and
hematological malignancies.7,33 In addition, our earlier data has
also suggested that AURKA was highly expressed in epirubicin
resistance breast tumor initiating cells and contributed to the
maintenance of stemness and drug resistance in breast cancer.34
Given the essential roles of AURKA overexpression in cancer
progression, targeting AURKA offers an attractive approach for
cancer therapy. In the present study, we found that AURKA could
override DNA-damaging agent-induced cell death in gastric
cancer cell lines, resulting in the development of drug resistance
which was at least partially mediated through Survivin
stabilization.
Gastrointestinal adenocarcinoma responds poorly to conven-
tional chemotherapy and has an unfavorable outcome if
diagnosed in an advanced stage.35 Therefore, it is vital to identify
early prognostic biomarkers and effective therapeutic targets for
gastric adenocarcinoma management. A number of epidemio-
logical studies have assessed AURKA expression in gastric
cancer.9,36–38 For example, in an analysis of 88 human primary
gastric tumor specimens, Kamada et al. reported positive staining
for AURKA in 41% of samples.9 Similarly, in an analysis of 130
gastric cancer subjects, 450% AURKA positivity was reported in
upper gastrointestinal adenocarcinoma.36 In the present study, we
analyzed a large cohort of 240 gastric cancer patient specimens
and found that AURKA was highly overexpressed in gastric cancer
tissues as assessed by immunohistochemistry and western
blotting (Figure 1a). Moreover, immunohistochemical analysis
showed that AURKA overexpression was correlated with tumor
stage, lymph node metastasis and distant metastasis, but not with
gender, age, tumor size, tumor site and tumor grading, suggestive
of a role of AURKA in gastric cancer progression. In agreement,
high AURKA expression was inversely associated with overall
survival of gastric cancer patients (Figure 1b) and had been shown
to be an independent prognostic factor for gastric cancer
(Figure 3c). This was consistent with our previous study in
laryngeal squamous cell carcinoma patients that elevated AURKA
expression predicted poor overall survival.39 Resistance to DNA-
damaging agent-induced apoptosis is a major mechanism of poor
chemotherapeutic response. Our study indicated that the limited
chemotherapy efﬁcacy might be due to high expression levels of
AURKA in gastric cancer. Consistent with this notion, over-
expression of AURKA in gastric cells could overcome DNA
damage-induced apoptotic cell death (Figure 1d), which again
was in agreement with another previous study.32 Recent reports
showed that AURKA overexpression was essential for the
tumorigenic capacity and drug resistance of breast tumor
initiating cells34 as well as chemoresistance in lung cancer
cells,40 supporting our study that deregulated overexpression of
AURKA in gastric cancer led to clinical chemoresistance.
As a member of IAPs, Survivin can confer drug resistance and is
correlated with drug refractory tumors.18,19,41,42 Survivin expres-
sion is signiﬁcantly upregulated in gastric cancers compared with
the tissues of normal mucosa, atrophic gastritis and intestinal
metaplasia, and is negatively associated with OS of patients who
received CDDP-based chemotherapy.43 Mechanistically, Survivin is
upregulated by upstream factors, such as p34/cdc2-cyclin B1 and
Plk1.44,45 In the present work, we demonstrated that inhibition of
AURKA kinase activity by VX-680 or depletion of total AURKA,
suppressed Survivin expression, whereas overexpression of AURKA
upregulated Survivin in gastric cancer cells (Figures 2a and b).
These ﬁndings are further corroborated by the ﬁnding that AURKA
and Survivin co-expressed in gastric cancer patients’ specimens
(Figure 2d). In addition, we also found that AURKA regulated
Survivin expression through suppression of its ubiquitylation
and proteasomal degradation (Figure 4). In previous reports,
AURKA has been shown to stabilize LIMPK2 in breast cancer46 and
N-myc in neuroblastoma26 by inhibiting their ubiquitylation and
degradation.
In dissecting molecular mechanism that leads to Survivin
upregulation in response to AURKA overexpression, we found
that Survivin upregulation by AURKA was not regulated at the
transcriptional level (Supplementary Figure 2). Previous studies
have shown that p53 represses Survivin transcription through
promoter hypermethylation.47 In our studies, VX-680 signiﬁcantly
suppressed Survivin protein levels in both the wild-type and p53
knockout MEFs, indicating the regulation of Survivin expression by
AURKA was unlikely to be dependent on p53.
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Survivin stabilization and upregulation by post-translational
modiﬁcations have been described previously.48,49 In a mass
spectrometry analysis of Survivin co-immunoprecipitates, we
found FBXL7 E3 ubiquitin ligase acted as a Survivin-interacting
protein. FBXL7 belongs to the leucine-rich repeats containing
F-box family of proteins and is a part of SCFs (SKP1-Cul1-F-box) E3
ligase complex. FBXL7 has been shown to induce the ubiquityla-
tion of AURKA during mitosis50 and Survivin in a cell cycle-
independent manner.48 FBXL7 is a potential tumor suppressor
gene as a previous study found an association between SNPs in
FBXL7 and an increased breast cancer risk.51 We showed that in
unsynchronized cells, FBXL7 promoted Survivin degradation by
proteasomal pathway in our experimental setting, which was in
agreement with a previous report,48 while AURKA expression
remained unaffected in response to FBXL7 overexpression.
Indeed, we found that both the FBXL7 mRNA and protein levels
increased in response to AURKA depletion in both AGS and
BGC823 cells. Basal levels of FBXL7 mRNA and protein were low in
gastric cancer cells and only became detectable after AURKA
depletion. This led us to speculate that FBXL7 was a potential
tumor suppressor gene and its expression was repressed by
AURKA in gastric cancer. We also found the FOXP1 transcription
factor to be an AURKA-interacting partner in the regulation of
FBXL7 transcription. This ﬁnding was in agreement with a previous
ChIP-sequencing analysis that FOXP1 bound to the FBXL7
promoter in vivo.52 In concordance, we found that FOXP1 could
activate FBXL7 promoter activity, while AURKA repressed the
FOXP1-mediated induction in FBXL7 promoter activity. Our In silico
analysis showed that FOXP1 was a potential AURKA substrate that
led us to speculate that AURKA could post-translationally modify
FOXP1 to alter its transcriptional activity. Since AURKA depletion
did not affect FOXP1 cytoplasmic/nuclear localization and
shuttling, we concluded that AURKA modulated FOXP1 without
affecting its (Supplementary Figure 3b and 3c) translocation.
Collectively, our data suggested that AURKA negatively regulated
FBXL7 expression through modulating the activity of the FOXP1
transcription factor and thereby, restricting Survivin degradation
by the FBXL7-ubiquitinylation complex (Figure 8).
Notably, inhibition of AURKA using the inhibitor VX-680
limited cell proliferation and that VX-680 synergized with the
DNA-damaging agent doxorubicin in suppressing cell proliferation
in BGC823 cells (Figure 3a). These results are concordant with
previous ﬁndings that AURKA suppression increased chemo-
sensitivity to docetaxel in both in vitro and in vivo models of
esophageal squamous cell carcinoma;53 however, the mechanism
underlying the AURKA-mediated chemotherapeutic resistance
remains enigmatic. Previous studies have shown that Survivin is
upregulated because of its cytoprotective function in response to
several anti-cancer agents, including doxorubicin, suggesting that
tumor cells enhance Survivin expression to counteract the
apoptotic signals induced by chemotherapeutic agents.42,54 In
our work, we found that doxorubicin alone induced Survivin
expression, while the combination of VX-680 and doxorubicin
induced apoptotic cell death synergistically in the human gastric
BGC823 cells, accompanied by a decrease in AURKA activation and
Survivin expression (Figure 3b). Collectively, our data suggest that
the synergistic cytotoxic effect of AURKA inhibition and doxor-
ubicin is possibly attributable to a convergence of signals that
ultimately lead to the downregulation of the expression of the
anti-apoptotic protein Survivin. This data proposes the inclusion of
AURKA inhibitors as therapeutic agents for gastric cancer
management. In conclusion, our data suggest that AURKA limits
Survivin ubiquitylation and degradation in gastric cancer and
provide a novel therapeutic target to promote the efﬁcacy of DNA-
damaging agent in gastric cancer.
MATERIALS AND METHODS
Cell culture, plasmids and transfections
Gastric cell lines AGS and BGC823 were cultured in RPMI 1640 (Gibco,
Carlsbad, CA, USA) HEK293T and mouse embryonic ﬁbroblast (MEF) were
cultured in Dulbecco's modiﬁed eagle medium (DMEM) (Gibco). Cell
culture media were supplemented with 10% heat-inactivated fetal bovine
serum (Gibco), 100 U/ml ampicillin and 100 μg/ml streptomycin (Gibco).
Treatments with doxorubicin (Sigma-Aldrich, St Louis, MO, USA), doxycy-
cline (Clonetech, Shiga, Japan), VX-680 (Selleck Chemicals, Kava Technol-
ogy), cycloheximide (Amresco, Solon, OH, USA) and MG132 (Sigma-Aldrich)
were carried out as indicated. Cells were transfected using lipofectamine
2000 transfection reagent (Invitrogen, Carlsbad, CA, USA). For details,
see Supplementary Materials and Methods.
Patients and clinical tissue specimens
See Supplementary Materials and Methods
Immunoblotting and immunoprecipitation
Cells, gastric cancer tissues and paired normal adjacent tissues were lysed
on ice with RIPA buffer. For further details, see Supplementary Materials
and Methods. Detailed information about the antibodies used in this study
is listed in Supplementary Table 4.
Immunoﬂuorescence staining
Immunoﬂuorescence staining was performed as described.55 For details,
see Supplementary Materials and Methods.
Immunohistochemical staining
Both staining intensity and extent were included to evaluate AURKA or
Survivin expression. Evaluation was done by at least two independent
pathologists. Moderate or strong cytoplasm staining was considered as
positive reaction. In analysis, specimen was determined as high staining
when 430% cells showed visible brown granules.
Figure 8. Schematic model of a proposed mechanism showing
how AURKA suppresses Survivin protein degradation. Survivin
undergoes proteasomal degradation mediated by SCFFBXL7 E3
ligase. However, AURKA downregulates FBXL7 expression through
modulation of FOXP1. Consequently, Survivin is stabilized and have
an important role in gastric cancer cell survival and drug resistance.
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Cell survival (MTT) assay
Cells were seeded into 96-well ﬂat bottom plates and exposed to increasing
doses of VX-680 (Kava Technology, San Diego, CA, USA), doxorubicin (Sigma-
Aldrich) separately or combination. Standard 3-(4,5-Dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assay was performed.
TUNEL assay
Cells were seeded in a 6-well plate, collected and ﬁxed with 4%
paraformaldehyde (Sigma-Aldrich) for 30 min. Cells were then labeled by
TdT-mediated dUTP Nick-End Labeling Kit (BD Biosciences, San Jose, CA,
USA) and analyzed on a Beckon Dickinson FACScan.
Evaluation of drug interactions
The interaction between VX-680 and doxorubicin was analyzed to
determine whether the combination was additive or synergistic. This
program is based on the Jin’s method, which is performed based on the
following equation: q=D1+2/(D1+D2−D1×D2), where D1+2 indicates the
effect when cells were used in combination with drug 1 and 2, and D1 or
D2 indicates the effect when used alone.
GST pulldown for identifying interacting transcription factors with
AURKA
To identify transcription factors that interact with AURKA, 500 μg AGS cells
nuclear extract, prepared as described previously.8 In-gel digestion and
recovery of peptides were performed as described earlier.56 For details,
see Supplementary Materials and Methods.
In vitro ubiquitylation assay
The in vitro ubiquitylation assay was performed in a volume of 50 μl
containing 50 mM Tris pH 7.6, 0.5 m DTT, 5 mM MgCl2, 2 mM ATP, 50 nM E11,
0.5 μM UbcH5B, 0.5 μM UbcH5C, 0.5 μM UbcH7, 2 μM ubiquitin-Flag,
20 nM Rbx1, 20 nM Cul1, 20 nM Skp1, 20 nM FBXL7, 200 nM Survivin at
room temperature for 1 h. Reaction was stopped by addition of SDS–PAGE
loading buffer and Survivin ubiquitylation visualized by immunoblotting
with Flag antibody.
ChIP assay
ChIP assay was performed as previously described.57 For details,
see Supplementary Materials and Methods.
RNA extraction and RT–qPCR assays
Total RNA was prepared using TRIzol (Invitrogen), according to
manufacturer’s instructions. For details, see Supplementary Materials and
Methods. Primers were purchased from Invitrogen and primer sequences
are listed in Supplementary Table 4.
In silico protein–protein interaction
Tertiary-structure-based in silico protein–protein interaction between
AURKA and FOXP1 was determined by PRISM method which is based on
template matching with known protein structures.29,30 We obtained PDB
ﬁles; 2 × 81 (AURKA) and 2KIU (FOXP1) as a target set of proteins and
analyzed their predicted protein–protein interaction as described
elsewhere.58
Promoter assay
Promoter dual luciferase assays (Promega, Madison, WI, USA) were
performed as per manufacturer’s instructions. For details, see
Supplementary Materials and Methods.
Statistical analysis
Statistical analysis was performed using SPSS v. 16.0 (SPSS, Chicago, IL,
USA). All P-values quoted were two-sided. Po0.05 was considered
statistically signiﬁcant.
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